|
Match
|
Document |
Document Title |
|
|
7605156 |
Methods for the use of inhibitors of cytosolic phospholipase A2
This invention provides methods for the use of substituted indole compounds of the general formula:
and pharmaceutically acceptable salt forms thereof. The invention provides methods for the...
|
|
|
7601747 |
One-pot process for making di-functional di-tetrazole diols to produce tetrazole based polymers
A one-pot process for making energetic cast cured binders making di-tetrazoles to produce di-functional di-tetrazole diols for making tetrazole base polymers. Embodiments of the present invention...
|
|
|
7592366 |
Therapeutic compounds
A compound having a formula
is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
|
7592337 |
Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring,...
|
|
|
7576112 |
Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives
A compound having a structure
and therapeutic methods, compositions, and medicaments related thereto are disclosed herein.
|
|
|
7576098 |
Heterocyclic compounds as inhibitors of factor VIIa
The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable...
|
|
|
7572922 |
Substituted pyrazoles, compositions containing such compounds and methods of use
The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for...
|
|
|
7563804 |
FMF treatment
The method of improving FMF control, in humans, which includes administering, on an average daily basis, between 5 and 15 milligrams of LTRA to a patient suffering from FMF.
|
|
|
RE40861 |
Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
Compounds of formula (I)
wherein the groups are as defined in the description are disclosed.
The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine...
|
|
|
7557244 |
Substituted biphenyl carboxylic acids and derivatives thereof
The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 given below, and/or a salt or ester thereof....
|
|
|
7553861 |
Dipeptidyl peptidase-IV inhibitors
The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods...
|
|
|
7550448 |
Therapeutic compounds
Disclosed herein is a compound having a structure
or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also...
|
|
|
7538133 |
Benzimidazole derivatives, their production and use
Benzimidazole derivatives of the formula (I):
wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R 1 is hydrogen or an optionally...
|
|
|
7538128 |
Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula:
wherein X, Y, a, R 1 , and R 2 are as defined herein.
|
|
|
7528156 |
Compounds
The invention provides compounds of general formula (D wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification, processes for their preparation,...
|
|
|
7521470 |
Factor Xa inhibitors
The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The...
|
|
|
7517998 |
Non nucleoside reverse transcriptase inhibitors
Compounds of formula (I):
wherein Ar, X, R 1 , R 2 , R 3 and R 4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double...
|
|
|
7517896 |
Aminodicarboxylic acid derivatives having pharmaceutical properties
The invention relates to compounds of formulae (II), (IV), and (VI) as shown below,
wherein the several variable groups are as defined in the specification and claims. Processes for making...
|
|
|
7514438 |
Melanin concentrating hormone receptor antagonist
Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I
wherein A, W, X, Z, R 1 -R 3 , and R 8 are as defined in the specification, are provided....
|
|
|
7491741 |
Diaminopropionic acid derivatives
A compound of formula 1a
which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.
|
|
|
7482470 |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity,...
|
|
|
7482371 |
N-phenylbenzamide derivatives as drugs for the treatment of COPD
The invention relates to the use of a pharmaceutically active derivative of N-phenylbenzamide of Formula (I) or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the...
|
|
|
7476755 |
Therapeutic compounds
Therapeutic substituted cyclopentane compounds, and compositions, medicaments, and therapeutic methods related thereto are disclosed herein.
|
|
|
7468390 |
Methods of treatment and pharmaceutical composition
The invention relates a pharmaceutical composition comprising a combination of:
(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a...
|
|
|
7452874 |
Thrombopoietin mimetics
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating...
|
|
|
7439261 |
Process for the preparation of valsartan and intermediates thereof
A novel process for the preparation of valsartan and novel intermediates useful in the preparation thereof.
|
|
|
7425640 |
Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
The present invention provides compounds of formula I wherein X, Y, R 1 -R 7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA...
|
|
|
7414071 |
Methods of treatment with selective EP4 receptor agonists
The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the...
|
|
|
7414068 |
Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The...
|
|
|
7378433 |
N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
The present invention is concerned with compounds of formula
the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R 1 is...
|
|
|
7365085 |
Compounds and methods
Disclosed is a compound having the formula:
pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are...
|
|
|
7361672 |
Heteroarylacetamide inhibitors of factor Xa
The invention is concerned with novel heteroarylacetamides of formula (I)
R d —C(O)—N(R e )—R c —CH 2 —C(O)—N(R a )(R b ) ...
|
|
|
7351730 |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
This invention provides PAI-1 inhibiting compounds of Formula I:
wherein: R 1 , R 2 , R 3 , and R 4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R 8 ,...
|
|
|
7351729 |
JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective...
|
|
|
7348333 |
Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
There are described cycloalkyl derivatives of the formula (I)
R 1 —Y-A-B-D-E-F-G (I)
|
|
|
7348322 |
Glucocorticoid receptor modulators as antiinflammatory agents
The present invention relates to compounds of formula I:
wherein A, X, R 1 , R 2 and R 3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to...
|
|
|
7345095 |
Sulfonamide compounds for the treatment of neurodegenerative disorders
The present invention relates to compounds of the Formula I
wherein R 1 , R 2 , R 3 , m, and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The...
|
|
|
7345072 |
Phenyltetrazole compounds
Novel phenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists and the processes for the conversion thereof to biologically active molecules.
|
|
|
7345071 |
Process for the synthesis of Losartan potassium
Improved processes using primary, secondary and tertiary alcohols and with safer mode of introduction of the reagent and reaction conditions are described. Further, the process of manufacture of...
|
|
|
7342039 |
Substituted indole oximes
The present invention relates to substituted indole oximes and methods of using them.
|
|
|
7332516 |
Geminally di-substituted NSAID derivatives as Aβ42 lowering agents
The present invention encompasses compounds of Formula I (I)
or pharmaceutically acceptable salts thereof, wherein A is the base molecule of a propionic acid or acetic acid NSAID, or a...
|
|
|
7332514 |
Dibenzylamine compound and medicinal use thereof
A dibenzylamine compound represented by the formula (1)
wherein R 1 and R 2 are each a C 1-6 alkyl group optionally substituted by halogen atoms and the like; R 3 , R 4 and R 5 are each a...
|
|
|
7326732 |
EP2 receptor agonists
A compound of formula (I):
or a salt, solvate and chemically protected form thereof, wherein:
R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from...
|
|
|
7323483 |
Processes and compounds for the preparation of substituted naphthylindole derivatives
The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain...
|
|
|
7323480 |
Substituted triazoles as modulators of PPAR and methods of their preparation
The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention...
|
|
|
RE40000 |
Method of treatment for decreasing mortality resulting from congestive heart failure
A method of treatment using a compound of Formula I:
wherein:
R 1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R 2 is hydrogen,...
|
|
|
7307078 |
Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof
Novel polycyclic compounds having the structural formula (I) below:
are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology,...
|
|
|
7291623 |
Compounds that interact with kinases
A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose...
|
|
|
7285565 |
Benzamides and related inhibitors of factor Xa
Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or...
|
|
|
7279478 |
Cathepsin cysteine protease inhibitors
This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating...
|